Now there’s an FDA-approved, first-line treatment for adults with LEMS.1,2
INDICATIONS AND USAGE: FIRDAPSE® is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS FIRDAPSE® is contraindicated in patients with:
- A history of seizures
- Hypersensitivity to amifampridine phosphate or another aminopyridine
WARNINGS AND PRECAUTIONS Seizures: FIRDAPSE® can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE® in patients who have a seizure while on treatment. FIRDAPSE® is contraindicated in patients with a history of seizures. Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE® should be discontinued and appropriate therapy initiated. ADVERSE REACTIONS The most common adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Now there’s an FDA-approved, first-line treatment for adults with LEMS.1,2
INDICATIONS AND USAGE: FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
FIRDAPSE is contraindicated in patients with:
- A history of seizures
- Hypersensitivity to amifampridine phosphate or another aminopyridine
WARNINGS AND PRECAUTIONS
Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures.
Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.
ADVERSE REACTIONS
The most common adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.
To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
At Catalyst Pharmaceuticals, we understand that receiving a rare disease diagnosis can be extremely difficult. Often patients feel isolated and hopeless. That’s why we believe that, when you’re battling a rare disease—it’s all about the company you keep.
Our company is committed to developing novel, safe, and efficacious therapies that will improve the lives of people with rare and ultra-rare diseases.
Corporate Citizenship
Social responsibility is at the heart of everything we do
A Singular Mission
To improve the lives of patients with rare and ultra-rare diseases
Partnering With Patients
Empowering patients to take an active role in their health care
Cutting-Edge Science
The innovation behind a breakthrough